FindTrial
Sign In

AZD5305

DRUG5 trials

Sponsors

University of Leeds, AstraZeneca

Conditions

Additional Indications Below for Module 4 and 5Advanced Solid MalignanciesBiliary CancerBladder CancerBreast CancerCervical CancerColorectal CancerEndometrial Cancer

Phase 1

A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC
RecruitingNCT04550104
University of LeedsNon Small Cell Lung Cancer
Start: 2021-03-17End: 2028-03-31Target: 200Updated: 2025-12-19
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
Active, not recruitingNCT04644068
AstraZenecaAdditional Indications Below for Module 4 and 5, Biliary Cancer, Bladder Cancer +10
Start: 2020-11-12End: 2027-05-28Updated: 2026-02-19
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
Active, not recruitingNCT05367440
AstraZenecaMetastatic Prostate Cancer
Start: 2022-06-02End: 2031-04-11Updated: 2025-12-08
Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies
CompletedNCT05573724
AstraZenecaAdvanced Solid Malignancies
Start: 2022-11-07End: 2024-05-17Updated: 2024-06-18
A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs
Not yet recruitingNCT07336446
AstraZenecaProstate Cancer
Start: 2026-01-05End: 2029-01-04Target: 300Updated: 2026-01-13

Related Papers

Abstract 254: The PARP1-selective inhibitor and trapper saruparib achieves extended PARP1 target engagement <i>in vitro</i> , <i>in vivo</i> and in the clinic.
Cancer Research2026-04-03
Abstract PS1-10-28: Phase 1/2a trial of new generation PARP1-selective inhibitor saruparib + next generation selective ER degrader (SERD) camizestrant in patients (pts) with advanced/relapsed ER+/HER2-negative or low (HER2−) breast cancer (PETRA Module 6)
Clinical Cancer Research2026-02-17
Phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with androgen receptor pathway inhibitors in patients with metastatic hormone-sensitive prostate cancer with and without homologous recombination repair mutation (EvoPAR-Prostate01).
Journal of Clinical Oncology2025-02-102 citations
Phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with new hormonal agents in patients with metastatic castration-sensitive prostate cancer with and without homologous recombination repair mutation (EvoPAR-Prostate01).
Journal of Clinical Oncology2024-06-0111 citations
Abstract 5618: Evaluating the combination of datopotamab deruxtecan (Dato-DXd) with AZD5305, a highly potent, PARP1-selective inhibitor, -in preclinical models
Cancer Research2024-03-223 citations
PETRANHA: Phase 1/2 study of AZD5305 + novel hormonal agents in patients with metastatic prostate cancer–Interim safety and pharmacokinetic results.
Journal of Clinical Oncology2024-01-297 citations
Modulatory Potential of Poly (ADP‐Ribose) Polymerase 1 (PARP1) in BRCA‐Mutated Tumors
European Journal of Cancer Care2024-01-011 citations
Abstract CT269: A highly sensitive and specific PARylation assay confirms significant and durable target engagement by AZD5305 in patients
Cancer Research2023-04-14
Phase 1/2a study of AZD5305, a novel poly(adenosine diphosphate ribose) polymerase (PARP) 1-selective inhibitor in combination with new hormonal agents (NHAs) in patients (pts) with metastatic prostate cancer (mPC).
Journal of Clinical Oncology2023-02-205 citations
Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper
Clinical Cancer Research2022-08-05154 citations
Abstract CT007: PETRA: First in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1/2, PALB2 or RAD51C/D mutations
Cancer Research2022-06-1562 citations